The ADAM8 protein is expressed on the cancer cell surface, downstream of the NF-κB family of transcription factors known to promote tumor growth, resistance to chemotherapy and metastasis. Consistently, ADAM8 is a critical driver of the growth and spread of many aggressive tumors, including those of the breast, stomach, colon, lungs, liver and pancreas, and is associated with poor patient survival. Currently, there is no approved therapy for patients with ADAM8-positive tumors or a diagnostic to identify them. Adecto’s initial focus is on breast cancer with a plan to expand to other oncology indications in the future. We estimate that globally over 2 million patients have an ADAM8-positive cancer and could benefit from our products.